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Abstract
Objective: We evaluated whether first-trimester high-sensitivity C-reactive protein (hsCRP), a suggested marker of pregnancy-
associated hyperglycemia, predicts third-trimester impaired glucose tolerance (IGT) in a secondary analysis of a prospective
cohort of nondiabetic singletons enrolled at <26 weeks gestation. Study Design: We measured the association between
hsCRP collected at <14 weeks among women classified as IGT (gestational diabetes screening results, 135 to <200 mg/dL) and
those among normoglycemic women. Multivariable modeling estimated the association between log hsCRP and IGT, adjusted for
maternal body mass index (BMI). Results: Among 300 women, 13% (39 of 300) had IGT. The hsCRP was positively associated
with glucose (P ¼ .005). Compared with normoglycemic women, women with IGT had higher log hsCRP (0.87 + 0.66 vs 0.67 +
0.60, P ¼ .04), but the association was not significant in adjusted models (adjusted odds ratio 1.20, 95% confidence interval
0.65-2.21). The hsCRP did not predict third-trimester IGT in this analysis when BMI is considered. Conclusion: Early identifi-
cation of women at risk of IGT remains a priority, but the contribution of maternal BMI appears greater than hsCRP.
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Introduction
Impaired glucose tolerance (IGT) in pregnancy and gestational
diabetes (GDM) are associated with adverse perinatal outcomes
and is a significant, growing public health challenge.1 Maintain-
ing glycemic control in pregnancy has short- and long-term
health benefits for maternal and child health.2,3 However, cur-
rent third-trimester glucose intolerance screening leaves limited
time for intervention if IGT or GDM is diagnosed. Earlier iden-
tification of glucose intolerance risk may increase time for inter-
vention and offer opportunities for prevention.4
Maternal serum markers, measureable early in pregnancy
and in routine clinical practice, have been suggested as promis-
ing predictors of later pregnancy glucose intolerance.4,5 High-
sensitivity C-reactive protein (hsCRP) is an acute-phase
reactant that, at subclinical elevations, is a marker for endothe-
lial damage, cardiovascular disease, and obesity in nonpreg-
nant patients.6,7 In pregnancy, hsCRP is associated with
maternal serum glucose when measured at the time of standard
third-trimester GDM screening.5,8,9
Current data on hsCRP are limited to at-risk populations
with few that assess early pregnancy measurements. Whether
first-trimester hsCRP is associated with third-trimester glu-
cose, and thus a potential early pregnancy serum marker, is
unknown. We evaluated whether first-trimester hsCRP is pre-
dictive of third-trimester GDM screening result among
women diagnosed with IGT.
Materials and Methods
We performed a secondary analysis of nondiabetic pregnant
women enrolled in a cross-sectional prospective study of oral
health in pregnancy. The study design and methods of the
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primary study have been described previously.10,11 As part of
the primary study protocol, women with greater than singleton
pregnancy, type 2 diabetes mellitus, chronic hypertension, or
medical comorbidities likely to impact early pregnancy hsCRP
values (ie, liver or renal diagnoses and HIV) were not eligible
for study inclusion. Maternal demographic and medical history
data, including measured height and weight for body mass
index (BMI) calculation, were collected through interviews
and written questionnaire at enrollment. Maternal race was
recorded as white, black, or other by patient self-report.
During the 42-month study period of the primary study,
starting in December 1997, 63% (1224 of 1945) of eligible
women were consented at <26 weeks with ultrasound-
confirmed gestational age. After exclusion of women without
serum CRP, or fetal loss or spontaneous abortion >21 weeks,
study withdrawal, or transfer for delivery at another hospital,
1020 remained enrolled. Women were followed through deliv-
ery and delivery outcomes were collected as part of the original
study protocol. For the current secondary analysis, we included
women with hsCRP collected at <14 weeks who also had GDM
screening (50 g; 1-hour oral glucose load) at 24 to 28 weeks
gestation. Women with GDM screening results of 135 to
<200 mg/dL but without GDM were classified as IGT. Ten
women diagnosed with GDM were excluded from the analysis.
Maternal serum was collected at enrollment to determine
hsCRP, using a previously published technique.12 This was a
commercially available, highly sensitive enzyme-linked immu-
nosorbent assay (VIRGO C-reactive Protein Kit; Hemagen
Diagnostics, Waltham, Massachusetts). This assay’s range is
0.5 to 50 mg/mL, with inter- and intra-assay variability of 3%
and 15%, respectively. Duke University Medical Center Insti-
tutional Review Board approval was obtained for the original
study and for the current secondary analysis.
We described the final cohort, comparing women with and
without IGT, using Student’s t-test and chi-square analysis. The
hsCRP values were not normally distributed and were log-
transformed to approximate a normal distribution. We assessed
the unadjusted and adjusted linear relationship of log hsCRP and
glucose. We evaluated test-for-trend of mean hsCRP result for
each one standard deviation (SD) increase in glucose. Mean log
hsCRP was compared between normal women and women with
IGT. Multivariable modeling estimated the association of log
hsCRP and IGT. Of potential confounders assessed in bivariate
analysis, only maternal BMI remained significant and was
included in adjusted linear and multivariable models. Logistic
regression was used to generate a receiver–operating curve
(ROC) to identify whether a specific cut point existed for hsCRP,
maternal BMI, or the combination of both to optimally predict
IGT. The c-statistic or area under the curve (AUC) is reported.
Results
Among 300 women meeting inclusion criteria for this second-
ary analysis, mean glucose result was 107 + 26 mg/dL, and
13% (39 of 300) had IGT. Women with IGT, compared with
normoglycemic women, had greater enrollment BMI (29.8 +
7.4 kg/m2 vs 26.1 + 5.7 kg/m2, P ¼ .005), and the mean gesta-
tional age of enrollment among all women was 10.6 weeks.
Women with IGT were approximately 2 years older than nor-
moglycemic women (30.7 + 6.3 vs 28.5 + 6.1 years, P ¼
.04). Other demographic variables were similar among women
with and without IGT and are shown in Table 1.
In unadjusted linear regression, hsCRP was positively asso-
ciated with glucose result (r2 ¼ .03, P ¼ .005), but the associ-
ation was attenuated when enrollment BMI was considered
(P ¼ .25). Five categories of glucose result were created
according to the SD of 26 mg/dL among the cohort. The test-
for-trend was significant in unadjusted analysis (P ¼ .01),
demonstrating that first-trimester serum hsCRP correlated
with third-trimester maternal glucose levels. The trend did
not remain significant after adjusting for enrollment BMI
(P ¼ 0.31; Table 2)
Compared with normal women, those with IGT had higher
log hsCRP (0.87 + 0.66 vs 0.67 + 0.60, P ¼ .04). In unad-
justed multivariable logistic regression, log hsCRP was associ-
ated with IGT (odds ratio [OR] 1.70 95% confidence interval
[CI] 1.01-2.99). Once adjusted for enrollment BMI, the associ-
ation was not significant (adjusted OR 1.20 95% CI 0.65-2.21).
As shown in Figure 1, hsCRP had an AUC of 0.59 as an indi-
vidual marker of IGT. Maternal BMI had an AUC of 0.66.







n ¼ 39 Normoglycemic vs IGT
Mean + SD or n (%) P
Maternal age at enrollment, years 28.8 + 6.1 28.5 + 6.1 30.7 + 6.3 .04
Ethnicity
White 165 (55) 147 (56) 18 (46)
Black 116 (39) 100 (38) 16 (41)
Other 19 (6) 14 (5) 5 (13) .16
Parous 178 (59) 153 (59) 25 (64) .52
Gestational age at enrollment/serum collection, weeks 10.6 + 2.1 10.6 + 2.1 10.5 + 2.0 .83
Enrollment BMI, kg/m2 26.6 + 6.0 26.1 + 5.7 29.8 + 7.4 .005
Gestational age at GDM screening, weeks 26.8 + 6.1 26.3 + 2.2 24.7 + 5.1 .07
Abbreviations: IGT, impaired glucose tolerance; BMI, body mass index; GDM, gestational diabetes; SD, standard deviation.
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Combining hsCRP with maternal BMI marginally increased
overall AUC to 0.67.
Discussion
Among women undergoing routine third-trimester GDM
screening, IGT was a prevalent outcome. The hsCRP, mea-
sured in the first trimester, has some association with GDM
screening result among women with IGT. However, when early
pregnancy maternal BMI is considered, the contribution of
hsCRP is attenuated and not stronger than BMI.
Strengths of our analysis include its analysis of rigorously
collected prospective data, avoiding potential errors in clinical
chart abstraction or participant recall bias after an IGT diagno-
sis. The original prospective cohort included data on potential
mediators and confounders that could impact CRP or IGT diag-
nosis, and we were able to consider these in our analysis. The
original cohort was not specified as high risk for glucose intol-
erance or GDM so mirrors clinical practice where providers do
not clearly know who is at risk as early as first trimester. None-
theless, we were able to measure a prevalent clinical outcome,
IGT, that typically goes untreated but has known negative con-
sequences for maternal, fetal, and child health.
Study limitations must also be considered. Although we
have early pregnancy measured height and weight to calculate
BMI, we do not know gestational weight gain through time of
GDM screening. If women diagnosed with IGT, compared with
normoglycemic women, had gained more weight as of GDM
screening, this may further attenuate the adjusted association
between hsCRP and GDM screening result. We do know, how-
ever, that total gestational weight gain was similar between
normoglycemic and IGT women. Thus, it is plausible that
weight gain among this cohort was similar at time of GDM
screening. In this sample size, we were unable to measure the
association between hsCRP and a diagnosis of GDM. However,
finding an association with IGT suggests an even greater asso-
ciation if GDM versus normoglycemic women were compared
in a larger sample. In addition, data were not collected on fam-
ily history of diabetes mellitus or personal history of GDM.
However, as the primary analysis was the association between
first-trimester hsCRP and IGT, this history would not likely
have impacted overall findings.
Others have shown an association between hsCRP and
degrees of glucose intolerance. Smirnakis et al reported a
first-trimester nonfasting hsCRP was greater among women
who later developed GDM than with normoglycemic women.8
Retnakaran, et al., found hsCRP was more closely associated
with BMI than components of an oral glucose tolerance test
(OGTT).9 However, this association was specific to hsCRP and
an OGTT, each measured in the third trimester, so may not par-
allel findings when hsCRP is measured earlier in pregnancy, as
hsCRP is known to increase with advancing gestational age.13
Each of these studies included smaller sample sizes, com-
pared with ours, and dichotomized outcomes of glucose intol-
erance versus normoglycemia, instead of measuring the
adjusted linear relationship between exposure and outcome as
we did. The large Hyperglycemia and Adverse Pregnancy Out-
comes (HAPO) Study did assess linear relationships in a sec-
ondary analysis of inflammatory mediators. The authors
reported a linear relationship between second-trimester hsCRP
and components of the 2-hour OGTT test, even when adjusted
for BMI.14 That large analysis of third-trimester measurements
helps establish the plausibility of our analysis, seeking whether
early pregnancy hsCRP predicts later IGT.
Although our data examined a much smaller sample size,
our exposure, hsCRP, was measured in the first trimester. We
explored whether this serum marker could be an early preg-
nancy predictor of later IGT. Measurement of IGT, a prevalent
outcome that is primarily left untreated but also linked to the
Figure 1. Receiver–operating curve (ROC) for unadjusted and
adjusted logistic regression models.








<81 38 0.54 + 0.56 8.10 + 3.6
81-<107 128 0.66 + 0.59 11.6 + 2.0
107-<133 93 0.72 + 0.59 12.9 + 2.3
133-<159 28 0.85 + 0.63 17.3 + 4.2
>150 13 0.92 + 0.73 21.6 + 6.2
Abbreviations: BMI, body mass index; SD, standard deviation.
aUnadjusted P ¼ .01; adjusted for enrollment BMI P ¼ .31.
bAbsolute hsCRP shown as clinical reference.
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same adverse outcomes as GDM, highlights a different group
who may be amenable to treatment or prevention efforts. In a
nonpregnant population at risk of type 2 diabetes mellitus,
some data suggest modifying diet and exercise can prevent
diagnosis. Thus far, similar efforts have not been consistent
among pregnant women, and development of IGT has not been
prioritized as an outcome. We speculate that, before interven-
tions can be critically appraised, we need to better identify
at-risk women. Inflammatory mediators may extend the predic-
tive ability of traditional risk factors such as BMI.
High-sensitivity C-reactive protein has been implicated as a
predictor of type 2 diabetes mellitus, given that subclinical
inflammation is part of diabetes mellitus pathophysiology.
Gestational diabetes or IGT, as potential precursors to type 2
diabetes mellitus, may also have subclinical CRP elevation.
Perhaps glucose intolerance in pregnancy is a transient
unmasking of a latent metabolic syndrome.
Our data, in conjunction with these associations outside of preg-
nancy, have implications for future research. Current clinical prac-
tice leaves little time for intervention that may decrease the poor
perinatal outcomes associated with hyperglycemia. Perhaps the
debate over third-trimester GDM screening nuances should shift
to identifying earlier pregnancy variables that can predict IGT or
GDM before these diagnoses occur. The hsCRP may be one
inflammatory and insulin resistance marker present as early as the
first trimester. Our findings support maternal BMI as an integral
component of the association between first-trimester hsCRP and
IGT, although neither individually predicted IGT in our sample.
The greatest AUC shown in our ROC curve was 0.67 and predomi-
nantly driven by maternal BMI, not hsCRP. We speculate that a
combination of maternal characteristics in conjunction with early
pregnancy inflammatory markers may optimize IGT prediction.
Impaired glucose tolerance and GDM remain a public health prior-
ity, and earlier pregnancy identification of at-risk women has the
potential to increase time for intervention, or prevention, efforts.
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